468 related articles for article (PubMed ID: 28735357)
1. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
4. Pharmacovigilance in Europe: Place of the Pharmacovigilance Risk Assessment Committee (PRAC) in organisation and decisional processes.
Laroche ML; Batz A; Géniaux H; Féchant C; Merle L; Maison P
Therapie; 2016 Apr; 71(2):161-9. PubMed ID: 27080834
[TBL] [Abstract][Full Text] [Related]
5. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
[TBL] [Abstract][Full Text] [Related]
6. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
7. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
8. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
9. Obstacles to transparency over pharmacovigilance data within the EMA.
Prescrire Int; 2015 Nov; 24(165):278-9. PubMed ID: 26688911
[TBL] [Abstract][Full Text] [Related]
10. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
[TBL] [Abstract][Full Text] [Related]
11. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
Holm JEJ; Ruppert JG; Ramsden SD
Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
[TBL] [Abstract][Full Text] [Related]
12. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
[TBL] [Abstract][Full Text] [Related]
13. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
14. EU's new pharmacovigilance legislation: considerations for biosimilars.
Calvo B; Zuñiga L
Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
[TBL] [Abstract][Full Text] [Related]
15. French pharmacovigilance: Missions, organization and perspectives.
Vial T
Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
[TBL] [Abstract][Full Text] [Related]
16. Risk management : a European regulatory perspective.
Moseley JN
Drug Saf; 2004; 27(8):499-508. PubMed ID: 15154823
[TBL] [Abstract][Full Text] [Related]
17. Safety signal detection: the relevance of literature review.
Pontes H; Clément M; Rollason V
Drug Saf; 2014 Jul; 37(7):471-9. PubMed ID: 24895178
[TBL] [Abstract][Full Text] [Related]
18. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications.
Tsintis P; La Mache E
Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
Baldo P; Francescon S; Fornasier G
Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
[TBL] [Abstract][Full Text] [Related]
20. Aims and approaches of Web-RADR: a consortium ensuring reliable ADR reporting via mobile devices and new insights from social media.
Ghosh R; Lewis D
Expert Opin Drug Saf; 2015; 14(12):1845-53. PubMed ID: 26436834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]